Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.
about
Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospitalRasd2 Modulates Prefronto-Striatal Phenotypes in Humans and 'Schizophrenia-Like Behaviors' in Mice.Prolonged and tunable residence time using reversible covalent kinase inhibitors.Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.Genetics of antipsychotic-induced weight gain: update and current perspectives.Drug-target residence time--a case for G protein-coupled receptors.Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.The drug-target residence time model: a 10-year retrospective.Estimation of kinetic and thermodynamic ligand-binding parameters using computational strategies.Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoThe Role of Target Binding Kinetics in Drug Discovery.Antipsychotic-induced hyperprolactinemia in Tourette syndrome.Parkinsonism Driven by Antipsychotics Originates from Dopaminergic Control of Striatal Cholinergic Interneurons.A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor.Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics.Development of novel fluorescent histamine H1-receptor antagonists to study ligand-binding kinetics in living cells.Label-free NMR-based dissociation kinetics determination.Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital.Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modellingModelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment modelsIn vitro and in silico analysis of the effects of D receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrationsBinding kinetics of cariprazine and aripiprazole at the dopamine D receptor
P2860
Q28237349-B489AED5-8AF9-44E7-9B49-2F49577AF0E6Q30364690-2C85262A-B394-4281-8BE9-FDE5F157A71CQ35756228-D4D8810C-C674-4413-8C91-2F879351670DQ38057963-56B966F1-8ED6-4F41-94B8-5B068EFA8B7FQ38166456-0B60045B-C033-4469-811B-8DA6688FBEB4Q38189272-7364CA20-FADA-49F6-BFDE-9EF6522EDFEFQ38611990-06C3D0F5-3AFF-4415-9A27-EDD2ABC17D6AQ38672210-F25AF2C4-45EF-4C34-928B-EB592623434DQ38737287-6EECADDB-9AD3-4BC4-A4AB-C7807F59F91BQ38822818-CD1D28DA-0E83-4438-A507-35553B1F84C4Q38949395-42B5436E-08B0-41FA-ADAB-E606805969DDQ39455909-3B83FE64-6EB9-4136-8B28-96E3F84342CAQ41831385-CA85122F-2EA6-44BC-83DF-81D608088089Q42003151-AD668EA7-1C8C-4FA8-8691-9515DDBCAEC3Q42369933-A1B0D5C0-E9D5-44DB-98D9-B1F404C4FDAFQ43569767-AF4839AA-EFAE-49E5-9400-B1E906F60D1FQ43783930-8D0E170E-D810-4723-B536-F7DA20DE5A6CQ47225761-D90DEDA5-1716-4FD7-A0BA-D10459E0B749Q47711109-AF3EFEBB-5BDA-4B13-B839-4AF6D721B2FAQ49969718-CFE49EFC-5791-4DF1-9436-D6073D907A77Q50674482-D9B868A3-A4B7-4DE8-B8EB-B21B06229CA7Q55232340-27CDBBC0-1B05-43BB-B93D-EA5F42A9A9DFQ56961708-AE2E2BA1-5F17-49D9-A4F5-F10A344548E6Q57126301-F3D501E4-99C4-40A9-A8D1-209781FA058BQ58703159-D29FEEF0-16BE-4846-B2E5-17053D1DB8C1Q58730805-55046FFF-B0AC-4CE7-BED9-CF47ABD08062
P2860
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@en
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@nl
type
label
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@en
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@nl
prefLabel
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@en
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@nl
P2093
P2860
P1476
Clozapine, atypical antipsycho ...... dopamine receptor antagonism.
@en
P2093
Georges Vauquelin
Patrick Vanderheyden
Philip Seeman
Sophie Bostoen
P2860
P2888
P304
P356
10.1007/S00210-012-0734-2
P577
2012-02-14T00:00:00Z